Advertisement
Table 3 Frequency of intrathecal IgM and IgA synthesis; IgM and IgA CSF/serum ratios; intrathecal IgM and IgA fractions; amount of locally produced IgM and IgA; and absolute CSF and serum IgM and IgA concentrations
| Units | Pattern I MS | Pattern II + III MS | Pattern II MS | Pattern III MS | AQP4-IgG+ NMO [48] | |
|---|---|---|---|---|---|---|
| QIgM > Qlim(IgM) | Patients | 3/9 (33.3) | 3/17 (17.6) | 3/12 (25) | 0/5 (0) | n.d. |
| QIgM > Qlim(IgM), LPs | Samples | 3/16 (18.8) | 5/30 (16.7) | 5/20 (25) | 0/10 (0) | 13/96 (14%) |
| QIgM, all LPs | – | 0.58 (0.26–1.5; 15) | 0.65 (0.1–14.1; 26) | 0.8 (0.1–14.1; 17) | 0.6 (0.5–5.8; 9) | 0.9 (0–40.5; 97) |
| QIgM, if positive | – | 0.8 (0.58–1.5; 3) | 9.8 (3.5–14.1; 5) | 9.8 (3.5–14.1; 5) | n.a. | 8.3 (1.2–40.5; 13) |
| IgMloc, all LPs | mg/L | 0 (0–0.27; 16) | 0 (0–9.24; 29) | 0 (0–9.24; 19) | 0 (0–0; 10) | 0 (0–35.3; 95) |
| IgMloc, QIgM positives | mg/L | 0.12 (0.05–0.27; 3) | 6.41 (0.86–9.24; 5) | 6.41 (0.86–9.24; 5) | n.a. | 0.9 (0–35.3; 13) |
| IgMIF, all LPs | % | 0 (0–0.12; 16) | 0 (0–0.86; 30) | 0 (0–0.86; 20) | 0 (0–0; 10) | 0 (0-95.8; 95) |
| IgMIF, QIgM positives | % | 0.1 (0.09-0.12; 3) | 0.71 (0.17–0.86; 5) | 0.71 (0.17–0.86; 5) | n.a. | 15.3 (2.3–95.8; 13) |
| IgM CSF, all LPs | mg/L | 1 (0.4–3; 15) | 1.05 (0.2–17.8; 26) | 1.2 (0.2–17.8; 17) | 0.9 (0.54–11; 9) | 0.7 (0–36.9; 100) |
| IgM CSF, QIgM positives | mg/L | 1.2 (0.42–3; 3) | 9 (5.4–17.8; 5) | 9 (5.4–17.8; 5) | n.a. | n.d. |
| IgM serum, all LPs | g/L | 1.68 (0.56–3.75; 16) | 1.6 (0.38–3.68; 29) | 1.45 (0.38–3.68; 20) | 1.7 (0.9–2.2; 9) | 0.96 (0.13–2.85; 99) |
| IgM serum, QIgM positives | g/L | 1.51 (0.72–2; 3) | 1.1 (0.64–1.5; 5) | 1.1 (0.64–1.5; 5) | n.a. | n.d. |
| QIgA > Qlim(IgA) | Patients | 2/8 (25) | 1/17 (5.9) | 1/12 (8.3) | 0/5 (0) | n.d. |
| QIgA > Qlim(IgA) | Samples | 2/15 (13.3) | 1/29 (3.4) | 1/19 (5.3) | 0/10 (0) | 5/88 (6%) |
| QIgA, all LPs | – | 1.77 (1.01–5.7; 13) | 2.5 (0.82–9.1; 29) | 2.4 (1–6.6; 19) | 3.3 (0.82–9.1; 10) | 2.1 (0–40.4; 88) |
| QIgA, if positive | – | 3.22 (1.73–4.7; 2) | 1 (1–1; 1) | 1 (1–1; 1) | n.a. | 5.1 (3.7–20.2; 5) |
| IgAloc, all LPs | mg/L | 0 (0–3.72; 15) | 0 (0–0.08; 29) | 0 (0–0.08; 19) | 0 (0–0; 10) | 0 (0–3.2; 86) |
| IgAloc, QIgA positives | mg/L | 2.015 (0.31–3.72; 2) | 0.08 (0.08–0.08; 1) | 0.08 (0.08–0.08; 1) | n.a. | 0.3 (0.03–3.2; 5) |
| IgAIF, all LPs | % | 0 (0–0.73; 15) | 0 (0–0.08; 29) | 0 (0–0.08; 19) | 0 (0–0; 10) | 0 (0–7.5; 86) |
| IgAIF, QIgA positives | % | 0.425 (0.12–0.73; 2) | 0.08 (0.08–0.08; 1) | 0.08 (0.08–0.08; 1) | n.a. | 5.6 (0.5–7.5; 5) |
| IgA CSF, all LPs | mg/L | 2.7 (1.4–16.6; 13) | 4.55 (0.24–19.9; 30) | 3.45 (0.24–17.5; 20) | 8.5 (3.1–19.9; 10) | 4.7 (0–131; 95) |
| IgA CSF, QIgA positives | mg/L | 3.79 (2.5–5.08; 2) | 1.1 (1.1–1.1; 1) | 1.1 (1.1–1.1; 1) | n.a. | n.d. |
| IgA serum, all LPs | g/L | 1.53 (0.9–2.9; 15) | 1.88 (0.53–3.8; 29) | 1.55 (0.53–3; 19) | 2.6 (1.2–3.8; 10) | 0.96 (0.13–2.85; 99) |
| IgA serum, QIgA positives | g/L | 1.26 (1.08–1.45; 2) | 1.1 (1.1–1.1; 1) | 1.1 (1.1–1.1; 1) | n.a. | n.d. |
